Ester Costa Larrión

Project Manager Human Health R&D Bioiberica


Recent insights reveal that the collagen market is expanding, creating exciting opportunities for dietary supplement manufacturers to innovate in the joint health sector. However, staying competitive in this evolving arena is challenging, especially when looking to develop novel solutions with widely researched ingredients that are also easy to formulate.
This presentation discusses evidence that  Collavant n2 - native (undenatured) type II collagen is effective in supporting joint health at low doses(only 40 mg/day)  therefore meeting increasing consumer demand for convenient products that support their health.
The efficacy of Collavant n2 has been assessed in 4 scientific studies which results will be explained at the presentation.